Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery to Support Blueprint Medicines' Cancer Research Platform

NEW YORK (GenomeWeb News) – Horizon Discovery announced today a research service agreement to deploy its X-MAN isogenic cell lines in support of Blueprint Medicine's "New Targets" discovery platform.

Blueprint is based in Cambridge, Mass., and develops highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will use its platform and expertise to screen certain Blueprint kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines, in the process providing insights into "elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes."

Blueprint has developed a platform combining genomics expertise with a novel library of kinase inhibitors that allows the development of "potent, highly selective compounds to address clear genomic driver targets," Horizon said.

Financial and other terms were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.